Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type  2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies

ConclusionTreatment with once-weekly dulaglutide improved glycemic control in patients with T2D aged ≥ 60 years and<  60 years and was well tolerated in older patients, suggesting it can be considered a safe and effective treatment option for use in older patients with T2D.Trial registrationAWARD-CHN1 (NCT01644500) and AWARD-CHN2 (NCT01648582).
Source: Diabetes Therapy - Category: Endocrinology Source Type: research